Vanda PharmaceuticalsVNDA
Market Cap: $274M
About: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Employees: 203
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
24% more capital invested
Capital invested by funds: $205M [Q1] → $255M (+$50.1M) [Q2]
15% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 34
4% more funds holding
Funds holding: 142 [Q1] → 147 (+5) [Q2]
7% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 46
8.92% less ownership
Funds ownership: 86.46% [Q1] → 77.54% (-8.92%) [Q2]
40% less call options, than puts
Call options by funds: $1.23M | Put options by funds: $2.04M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Cantor Fitzgerald Charles Duncan 58% 1-year accuracy 40 / 69 met price target | 176%upside $13 | Overweight Maintained | 1 Aug 2024 |
Cantor Fitzgerald Charles Duncan 58% 1-year accuracy 40 / 69 met price target | 134%upside $11 | Overweight Initiated | 11 Jul 2024 |
Financial journalist opinion
Based on 3 articles about VNDA published over the past 30 days